SecBot SecBot
S-3 ·Filed Nov 5, 2026

SCYX

SCYNEXIS INC
NEUTRAL
Impact 3/10
Horizonmonths Processed11d 18h ago SEC0001193125-26-448707
Shelf registration (potential dilution)
Actionable Insight • Neutral

This is a routine shelf replacement with no immediate capital raise. Monitor for future prospectus supplements that would signal an actual offering. The I.B.6 limitation restricts primary offerings to ~$17.5M in any 12-month period unless public float exceeds $75M, capping near-term dilution from primary offerings.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SCYX drug pipeline →

SCY-770

● Neutral Named in this S-3
Impact
Phase
Phase 1 completed; Phase 2 ready
Time to market
Minimum 3-4 years, assuming positive Phase 2 data drives Phase 3 and potential accelerated approval via FDA-recognized surrogate endpoint (total kidney volume)
Next catalyst
None dated

What to watchWatch for the Phase 2 proof-of-concept study initiation in Q4 2026 (imminent) and, more importantly, the early efficacy readout on total kidney volume expected in the second half of 2027. SCY-770 must demonstrate a meaningful reduction in kidney growth versus placebo to justify the valuation implied by analyst targets (~$36 mean). Until then, the stock is driven by SCY-247 antifungal progress and the $214M BARDA contract, SCY-770 remains a high-risk/high-reward pipeline component.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$3.30
T+0 close · Nov 5, 2026 · via day close
Latest settled
+0.91%
T+5 · $3.33
Vs SPY
−2.38%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $3.30entry
  2. T+1 · 11d ago +6.06%α +5.75% · $3.50
  3. T+5 · 5d ago +0.91%α −2.38% · $3.33
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SCYNEXIS filed a new S-3 shelf registration to replace its expiring 2023 S-3, carrying forward the full $200 million of unsold securities. No new securities or additional registration fees are involved. The filing is a routine administrative replacement that maintains the company's ability to raise capital through common stock, preferred stock, debt securities, or warrants over the next three years.

Key Financial Metrics

Offering Size
$200.0M

Key Facts

  • Filed S-3 to replace expiring S-3 (File No. 333-275520) due to expire November 27, 2026
  • Carrying forward $200,000,000 in unsold securities from the prior shelf; no new securities registered
  • No additional registration fee due; $29,520 in previously paid fees carried forward
  • Public float approximately $52.5 million as of November 3, 2026
  • Subject to General Instruction I.B.6 limiting primary offerings to one-third of public float ($17.5M) in any 12-month period unless public float exceeds $75M
  • Company is a clinical-stage biotech with lead programs SCY-770 (ADPKD) and SCY-247 (antifungal); only approved product BREXAFEMME licensed to GSK
  • 10-Q filed same day shows ongoing operating losses and need for capital to fund development

Financial Impact

Shelf capacity of $200 million maintained; no immediate capital raise

potential future dilutioncapital raising capacity

Risk Factors

  • Future offerings under this shelf could cause dilution to existing shareholders
  • Company has a history of frequent capital raises (4 offering/registration filings in last 24 months)
  • Clinical-stage biotech with no recurring product revenue and ongoing cash burn requires continued financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-448707
Document: d167987dexfilingfees.htm0001193125-26-448707
Document: d167987dex51.htm0001193125-26-448707
Document: d167987dex231.htm0001193125-26-448707
Document: 0001193125-26-448707-index-headers.html0001193125-26-448707
Document: 0001193125-26-448707-index.html0001193125-26-448707
Document: 0001193125-26-448707.txt0001193125-26-448707

Track record

14 reports on SCYX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
  2. Nov 5, 202611d ago S-3 Neutral 3/10 Viewing Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  4. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
  5. Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
  6. Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
  7. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
  8. Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
  9. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
  10. May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026